Steris hit with FDA warning letter

Steris' struggles with the FDA continue. The agency cited the company for making improper marketing claims about several steam-sterilization devices. The Feb. 9 warning letter alleges the Mentor, Ohio-based company misbranded its devices by making claims about their capabilities that were not cleared by the FDA as part of Steris' 510(k) applications. News

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.